Modified Apolipoprotein (apo) A-I by Artificial Sweetener Causes Severe Premature Cellular Senescence and Atherosclerosis with Impairment of Functional and Structural Properties of apoA-I in Lipid-Free and Lipid-Bound State

다국어 초록 (Multilingual Abstract)

Long-term consumption of artificial sweeteners (AS) has been the recent focus of safety concerns. However, the potential risk of the AS in cardiovascular disease and lipoprotein metabolism has not been investigated sufficiently. We compared the influence of AS (aspartame, acesulfame K, and saccharin) and fructose in terms of functional and structural correlations of apolipoprotein (apo) A-I and high-density lipoproteins (HDL), which have atheroprotective effects. Long-term treatment of apoA-I with the sweetener at physiological concentration (3 mM for 168 h) resulted in loss of antioxidant and phospholipid binding activities with modification of secondary structure. The AS treated apoA-I exhibited proteolytic cleavage to produce 26 kDa-fragment. They showed pro-atherogenic properties in acetylated LDL phagocytosis of macrophages. Each sweetener alone or sweetener-treated apoA-I caused accelerated senescence in human dermal fibroblasts. These results suggest that long-term consumption of AS might accelerate atherosclerosis and senescence via impairment of function and structure of apoA-I and HDL.

참고문헌 (Reference)

1 Benzie, I.F., "The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay" 239 : 70-76, 1996

2 Sasaki, Y.F., "The comet assay with 8 mouse organs: results with 39 currently used food additives" 519 : 103-119, 2002

3 조경현, "Synthesis of Reconstituted High Density Lipoprotein (rHDL) Containing apoA-I and apoC-III: the Functional Role of apoC-III in rHDL" 한국분자세포생물학회 27 (27): 291-297, 2009

4 Odegaard, A.O., "Soft drink and juice consumption and risk of physician-diagnosed incident type 2 diabetes: the Singapore Chinese Health Study" 171 : 701-708, 2010

5 Upmeier, E., "Serum lipids and their association with mortality in the elderly: a prospective cohort study" 21 : 424-430, 2009

6 Park, K.H., "Senescence-Related Truncation and Multimerization of Apolipoprotein A-I in High-Density Lipoprotein With an Elevated Level of Advanced Glycated End Products and Cholesteryl Ester Transfer Activity" GERONTOLOGICAL SOCIETY AMER 65 : 600-610, 2010

7 McPherson, J.D., "Role of fructose in glycation and cross-linking of proteins" 27 : 1901-1907, 1988

8 Ri-Zhong Zeng, "Protein Expression Changes in Human Monocytic THP-1 Cells Treated with Lipoteichoic Acid from Lactobacillus plantarum and Staphylococcus aureus" 한국분자세포생물학회 29 (29): 585-594, 2010

9 Ji, Y., "Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins" 270 : 11290-11297, 1995

10 Staros, J.V., "N-hydroxysulfosuccinimide active esters:bis(Nhydroxy-sulfosuccinimide)esters of two dicarboxylic acids are hydrophilic,membrane-impermeant,protein cross-linkers" 21 : 3950-3955, 1982

11 Fraenkal-Conrat, H., "Methods for investigating essential groups for enzyme activity" 4 : 247-269, 1957

12 Eberini, I., "Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini" 362 : 627-634, 2002

13 Pownall, H.J., "Kinetics of lipid-protein interactions:interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines" 17 : 1183-1188, 1978

14 Brewer, H.B. Jr., "Isolation and characterization of apolipoprotein A-I, A-II, and A-IV" 128 : 223-246, 1986

15 Scarmeas, N., "Invited commentary: lipoproteins and dementia - Is it the apolipoprotein A-I" 165 : 993-997, 2007

16 Walter, M., "Interrelationships among HDL metabolism, aging, and atherosclerosis" 29 : 1244-1250, 2009

17 Olney, J.W., "Increasing brain tumor rates: is there a link to aspartame? J. Neuropathol" 55 : 1115-1123, 1996

18 Oliveira-da-Silva, A., "Increased apoptosis and reduced neuronal and glial densities in the hippocampus due to nicotine and ethanol exposure in adolescent mice" 27 : 539-548, 2009

19 Mukherjee, A., "In vivo cytogenetic studies on mice exposed to acesulfame-K-a non-nutritive sweetener" 35 : 1177-1179, 1997

20 Jaleel, A., "Identification of de novo synthesized and relatively older proteins:accelerated oxidative damage to de novo synthesized apolipoprotein A-1 in type 1 diabetes" 59 : 2366-2374, 2010

21 DeGarmo, O., "Hydrolytic stability of saccharin" 41 : 17-18, 1952

22 Park, K.H., "High-density lipoproteins (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share pro-atherosclerotic and pro-senescent properties with increased cholesterol influx" 66 : 511-520, 2011

23 Park, K.H., "Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence" 392 : 295-300, 2010

24 Park, K.H., "Enhanced delivery of an adenovirus using proteoliposomes containing WT or V156K apolipoproteinA-I and dimyristoylphosphatidylcholine" 21 : 579-587, 2010

25 Feng, H., "Dysfunctional high-density lipoprotein" 16 : 156-162, 2009

26 Chen, Y.H., "Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion" 11 : 4120-4131, 1972

27 Nofer, J.R., "Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence" 3 : 1071-1086, 2005

28 Esterbauer, H., "Continuous monitoring of in vitro oxidation of human low density lipoprotein" 6 : 67-75, 1989

29 Reuber, M.D., "Carcinogenicity of saccharin" 25 : 173-200, 1978

30 조경현, "Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications" 한국생화학분자생물학회 42 (42): 393-400, 2009

31 Van den Eeden, S.K., "Aspartame ingestion and headaches:a randomized crossover trial" 44 : 1787-1793, 1994

32 Weihrauch, M.R., "Artificial sweeteners-do they bear a carcinogenic risk" 15 : 1460-1465, 2004

33 Eberini, I., "Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients" 39 : 306-311, 2007

34 "Apolipophorin III from Hyphantria cunea shows different anti-oxidant ability against LDL oxidation in the lipid-free and lipid-bound state" ELSEVIEW 151 (151): 433-439, 2008

35 "ApoA-I mutants V156K and R173C promote anti-inflammatory function and anti-oxidant activities" BLACKWELL PUBLISHING LTD 36 : 875-882, 2006

36 Liz, M.A., "ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity" 48 : 2385-2395, 2007

37 Rye, K.A., "Antiinflammatory actions of HDL: a new insight. Arterioscler" 28 : 1890-1891, 2008

38 조경현, "A point mutant of apolipoprotein A-I, V156K,anti-oxidant and anti-atherosclerotic activityhypercholesterolemic C57BL/6 mice" 생화학분자생물학회 39 (39): 160-169, 2007

39 Markwell, M.A., "A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples" 87 : 206-210, 1978

40 Dimri, G.P., "A biomarker that identifies senescent human cells in culture and in aging skin in vivo" 92 : 9363-9367, 1995